DNER and plasma cell myeloma: The small molecule BET protein inhibitors I-BET151 and I-BET762, belonging to the quinoline class of BET inhibitors, have also demonstrated in vitro activity in hematologic malignancies, including mixed lineage leukemia-related AML and multiple myeloma [21], [22].